lansoprazole has been researched along with Zollinger-Ellison Syndrome in 32 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Zollinger-Ellison Syndrome: A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "In these patients with the Zollinger-Ellison syndrome, pantoprazole was well tolerated and equally effective to the other proton pump inhibitors in terms of antisecretory potency." | 9.10 | Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 9.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "Lansoprazole was given for 3-48 months (median 28 months) to 26 Zollinger-Ellison syndrome patients with peptic ulcer manifestations in all and oesophagitis in 13." | 9.08 | Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "The aim of this prospective study was to confirm the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES)." | 9.08 | [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. ( Cadiot, G; Coste, T; Escourrou, J; Forestier, S; Mignon, M; Pospaï, D; Ruszniewski, P, 1998) |
| "Lansoprazole, a new substituted benzimidazole H+,K(+)-ATPase inhibitor, profoundly inhibits gastric acid secretion and has potential use in the management of diseases such as Zollinger-Ellison syndrome (ZES)." | 9.07 | Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. ( Feigenbaum, K; Gardner, JD; Jensen, RT; Koviack, PD; Maton, PN; Metz, DC; Pisegna, JR; Ringham, GL, 1993) |
| "The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome." | 9.07 | Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC, 1993) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 7.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 7.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| "Over a 20-year period, patients with Zollinger-Ellison syndrome were enrolled in a prospective trial evaluating the efficacy of lansoprazole." | 5.15 | Zollinger-Ellison syndrome: presentation, response to therapy, and outcome. ( Arcury, JT; Hirschowitz, BI; Mohnen, J; Seay, T; Wilcox, CM, 2011) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "In these patients with the Zollinger-Ellison syndrome, pantoprazole was well tolerated and equally effective to the other proton pump inhibitors in terms of antisecretory potency." | 5.10 | Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002) |
| "We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper." | 5.08 | Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "Lansoprazole was given for 3-48 months (median 28 months) to 26 Zollinger-Ellison syndrome patients with peptic ulcer manifestations in all and oesophagitis in 13." | 5.08 | Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996) |
| "The aim of this prospective study was to confirm the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES)." | 5.08 | [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. ( Cadiot, G; Coste, T; Escourrou, J; Forestier, S; Mignon, M; Pospaï, D; Ruszniewski, P, 1998) |
| "This paper aimed at evaluating the comparative efficacy of lansoprazole and omeprazole in reducing gastric acid secretion in patients suffering from Zollinger-Ellison syndrome." | 5.07 | [Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. ( Cadiot, G; Forestier, S; Joubert-Collin, M; Mignon, M; Paul, G; Ramdani, A; Ruszniewski, P; Vallot, T, 1994) |
| "Lansoprazole, a new substituted benzimidazole H+,K(+)-ATPase inhibitor, profoundly inhibits gastric acid secretion and has potential use in the management of diseases such as Zollinger-Ellison syndrome (ZES)." | 5.07 | Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. ( Feigenbaum, K; Gardner, JD; Jensen, RT; Koviack, PD; Maton, PN; Metz, DC; Pisegna, JR; Ringham, GL, 1993) |
| "The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome." | 5.07 | Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC, 1993) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| "To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e." | 4.79 | Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996) |
| "Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus." | 3.77 | Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992) |
| "Patients enrolled in a long-term trial of lansoprazole for Zollinger-Ellison syndrome and other acid hypersecretory states had interval histories taken every six months regarding hospitalizations or other intercurrent medical conditions." | 3.74 | Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole. ( Hirschowitz, BI; Martin, T; Mohnen, J; Phadnis, M; Wilcox, CM; Worthington, J, 2008) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 3.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| "To determine the efficacy of lansoprazole control of acid and pepsin secretion over the long term in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome hypersecretors." | 3.71 | Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2001) |
| "Relapse is infrequent and generally mild with acid secreting status closely monitored." | 2.75 | Costs and risks in the management of patients with gastric acid hypersecretion. ( Fineberg, N; Hirschowitz, BI; Mohnen, J; Wilcox, CM; Worthington, J, 2010) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| " Our group first performed a dose-response analysis of the efficacy of lansoprazole in reducing basal acid output (BAO) in four patients with severe Zollinger-Ellison syndrome (mean BAO 52 +/- 9 [SD] mmol H+/h) who had previously been treated with a mean omeprazole dosage of 75 mg/day." | 2.38 | Treatment of patients with Zollinger-Ellison syndrome. ( Forestier, S; Mignon, M; Pospai, D; Vallot, T; Vatier, J, 1993) |
| "We examined 27 patients with hypochlorhydria or achlorhydria based on a predefined basal acid output (BAO) measurement of less than 5." | 1.39 | Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( Metz, DC; Shah, P; Singh, MH; Yang, YX, 2013) |
| "We present a potential lansoprazole dosing regimen that should result in improved H." | 1.37 | CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication. ( Foster, DJ; Ward, MB, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (50.00) | 18.2507 |
| 2000's | 11 (34.38) | 29.6817 |
| 2010's | 5 (15.63) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, P | 1 |
| Singh, MH | 1 |
| Yang, YX | 1 |
| Metz, DC | 3 |
| Wilcox, CM | 4 |
| Martin, T | 1 |
| Phadnis, M | 1 |
| Mohnen, J | 10 |
| Worthington, J | 4 |
| Hirschowitz, BI | 12 |
| Fineberg, N | 1 |
| Seay, T | 2 |
| Arcury, J | 1 |
| Ward, MB | 1 |
| Foster, DJ | 1 |
| Arcury, JT | 1 |
| Simmons, J | 3 |
| Mayer, A | 1 |
| Sheiner, E | 1 |
| Holcberg, G | 1 |
| Haber, M | 1 |
| Dítĕ, P | 1 |
| Prásek, J | 1 |
| Jensen, RT | 3 |
| Fraker, DL | 1 |
| Paul, G | 1 |
| Ramdani, A | 2 |
| Mignon, M | 5 |
| Vallot, T | 2 |
| Forestier, S | 4 |
| Cadiot, G | 2 |
| Ruszniewski, P | 3 |
| Joubert-Collin, M | 2 |
| Arnold, R | 1 |
| Hochlaf, S | 1 |
| Vatier, J | 2 |
| Seifert, E | 1 |
| Pospai, D | 2 |
| Pisegna, JR | 1 |
| Ringham, GL | 1 |
| Feigenbaum, K | 1 |
| Koviack, PD | 2 |
| Maton, PN | 1 |
| Gardner, JD | 1 |
| Feigenbaum, KM | 1 |
| Shaw, S | 2 |
| Garnett, WR | 1 |
| Franko, TG | 1 |
| Richter, JE | 1 |
| Coste, T | 1 |
| Escourrou, J | 1 |
| Dobrilla, G | 1 |
| Capurso, L | 1 |
| Haber, MM | 1 |
| Bown, RL | 1 |
| Samoyeau, R | 1 |
| Barradell, LB | 1 |
| Faulds, D | 1 |
| McTavish, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
8 reviews available for lansoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
[Proton pump blockers and their significance in gastroenterology].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas | 1995 |
[Lansoprazole--profile of a new proton pump inhibitor].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1994 |
Treatment of patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; F | 1993 |
Lansoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans; | 1996 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
12 trials available for lansoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Costs and risks in the management of patients with gastric acid hypersecretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Endoscop | 2010 |
Presentation, response to lansoprazole therapy, and outcome of Zollinger-Ellison syndrome-like gastric acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Biopsy; Drug Administration Sched | 2011 |
Zollinger-Ellison syndrome: presentation, response to therapy, and outcome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Drug Adm | 2011 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
[Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Acid; Gastr | 1994 |
Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Aged; Anti-Ulcer Agents; | 1993 |
Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine Transaminase; Anti-Ulcer Agents; Aspar | 1993 |
Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors | 1996 |
Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Enzyme I | 1996 |
[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhib | 1998 |
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Ga | 2002 |
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer; | 1992 |
13 other studies available for lansoprazole and Zollinger-Ellison Syndrome
| Article | Year |
|---|---|
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Fe | 2013 |
Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti | 2008 |
CYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualization in H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cytochrome | 2011 |
Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastrinoma; Gastrins; Hum | 2007 |
Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromogranin A; Confounding Factors, Epi | 2007 |
Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Gastric Acid; Gastric Acidity Determination; Humans | 2008 |
Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Chemical Analysis; Combined Modali | 1994 |
Second proton-pump inhibitor marketed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan | 1995 |
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi | 1994 |
[Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Depression, | 1994 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema | 2001 |
Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Drug Administratio | 2001 |
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug; | 2002 |